{"slug":"vip-trigeminal","verification":{"valid":true,"entries":1,"head":"f5c9ada5f483a351bd528a7af5d158271235c36dec16615df9654d6282a68c5c"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.022494,"waste_cost_usd":0,"total_tokens":14985,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.022494,"tokens_total":14985,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:13:48.250Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Trigeminal Issues: Evidence on Repair Pathways","register":"source_ledger","body":"## What's breaking down\n\nTrigeminal neuralgia and related nerve issues often involve layers of degeneration in the trigeminal nerve and ganglion. One layer is mechanical or vascular compression that can lead to focal demyelination. Another is local inflammation that keeps nerves hyperexcitable. A third layer involves autonomic imbalance because parasympathetic fibers using VIP interact with trigeminal pathways. A fourth possible layer is reduced tissue repair signals after repeated irritation. When breakdown outruns repair at these layers, pain signals persist or amplify. VIP is discussed in research because it participates in immune modulation and autonomic signaling, not because it simply blocks sensation.\n\n## Why VIP might help you\n\nIf the immune and autonomic layer contributes to your trigeminal symptoms, VIP is studied for its potential role in tissue-level repair signals. Step one: elevated VIP appears in cerebrospinal fluid and blood during active trigeminal neuralgia episodes in people. Step two: VIP acts on VPAC receptors that can dampen certain inflammatory signals from Schwann cells and support neuron survival in lab models of nerve injury. Step three: if autonomic dysregulation or excess inflammation is driving your nerve irritation, this receptor activity might shift the balance toward repair rather than ongoing breakdown. Therefore for you: VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. VIP maps to the immune/autonomic layer listed above. If your profile also includes other degeneration layers such as direct myelin repair or central sensitization, additional compounds would target those separately without overlap in this article.\n\n## What the evidence actually shows\n\nHuman data: Zhao et al. (2002) measured VIP during trigeminal neuralgia attacks and noted changes in levels (human observation study). Qin et al. (2016) found significantly higher VIP concentrations in both cerebrospinal fluid and peripheral blood of primary trigeminal neuralgia patients compared with controls (human cross-sectional study). Bellamy (2004 thesis) reported correlations between VIP and CGRP in saliva during sinus-related trigeminal activation in humans. No completed human trials test VIP administration as treatment for trigeminal neuralgia.\n\nPreclinical data: Woodley et al. (2019) showed VIP up-regulation after peripheral nerve injury in mice and demonstrated VIP reduced pro-inflammatory cytokines in Schwann cells via VPAC receptors (animal study). Yan et al. (2025) examined VIP effects on trigeminal ganglion neuron excitability in cell models (preclinical mechanistic). Davis et al. (1987) showed trigeminal ganglion cells can express VIP under certain culture conditions (animal/cell study). These findings show VIP involvement in nerve injury responses but do not prove therapeutic benefit in living humans with trigeminal conditions.\n\nAnecdotal: Limited public reports tie VIP specifically to trigeminal neuralgia; one Reddit thread discusses VIP for broader inflammatory regulation but does not detail trigeminal outcomes.\n\n## What scientists say\n\nResearchers note VIP rises during trigeminal neuralgia attacks and migraine provocation studies, suggesting a role in cranial autonomic and sensory signaling. Human infusion studies (Pellesi 2021, Rahmann 2008) show VIP can dilate cranial vessels and sometimes provoke headache, highlighting its vasoactive effects without proving causation or treatment value for neuralgia. Preclinical work points to potential immunomodulatory and neurotrophic actions after nerve damage, yet authors emphasize the need for more targeted human research.\n\n## What people say on Reddit\n\nPublic discussions of VIP for chronic inflammatory or autonomic issues exist, but specific trigeminal neuralgia anecdotes remain sparse. Users sometimes mention interest in VIP for nervous system regulation without reporting resolved trigeminal symptoms.\n\n## What people say on X\n\nSearches yield minimal direct anecdotes linking VIP use to trigeminal neuralgia improvement or experiences. Occasional mentions appear in broader peptide or migraine contexts.\n\n## What we do not know\n\nNo randomized human trials exist that administer VIP to people with trigeminal neuralgia and measure pain or nerve function outcomes. Long-term safety and dosing data specific to this use case are absent. It remains unclear whether observed VIP level changes reflect cause, effect, or compensatory response. Animal nerve-injury models have not been replicated in trigeminal-specific human disease.\n\n## Safety and limits\n\nVIP infusions in research settings have produced headache and vasodilation in some participants. Individual responses vary. Evidence for any use in trigeminal conditions stays at the observational and preclinical stage. Readers should consult qualified professionals for personal health decisions.","claims":[{"id":"c1","text":"VIP concentrations are significantly higher in CSF and blood of primary trigeminal neuralgia patients versus controls","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Direct human measurement linking VIP to the condition","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:13:47.405Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"VIP levels change during trigeminal neuralgia attacks in patients","section":"What the evidence actually shows","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Observational human data on acute episodes","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:13:47.405Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"VIP up-regulation occurs after peripheral nerve injury and reduces inflammatory cytokines in Schwann cells in mouse models","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Animal evidence for repair-related mechanisms","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:13:47.405Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"VIP infusion can provoke headache and cranial vasodilation in human volunteers and migraineurs","section":"What the evidence actually shows","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Human provocation studies showing physiological effects","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:13:47.405Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.sciencedirect.com/science/article/abs/pii/S030384671630052X","title":"Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia","quote":"the concentrations of CGRP, SP, and VIP were significantly higher in TN patients as compared to those in the controls","link_status":"http_400","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/12593198/","title":"Observation of vasoactive intestinal polypeptide in patients with trigeminal neuralgia","quote":"During the attacks of trigeminal neuralgia the levels of VIP in the ...","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01326/full","title":"Distinct VIP and PACAP Functions in the Distal Nerve Stump Following Peripheral Nerve Injury","quote":"VIP and PACAP treatment not only inhibits TNFα, MCP-1, ILα, ILβ, and IL6 expression in Schwann cells","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"pubmed","url":"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782759","title":"Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Attacks","quote":"15 patients (71%) developed migraine attacks after VIP","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":11975,"tokens_out":3010,"cost":0.02249375,"prev_hash":"genesis","hash":"f5c9ada5f483a351bd528a7af5d158271235c36dec16615df9654d6282a68c5c"}]}